Avidity Biosciences at 75th American Academy of Neurology
Avidity Biosciences is a biotechnology company that is dedicated to developing therapies for rare muscle disorders and other serious illnesses. The company has announced that it will be presenting data from preclinical studies of its lead drug candidate, AOC 1001, at the upcoming 75th American Academy of Neurology Annual Meeting. AOC 1001 is an investigational therapy that utilizes Avidity’s proprietary technology to selectively target muscle cells and increase the production of dystrophin, a protein that is absent or defective in patients with Duchenne muscular dystrophy.
The preclinical data that Avidity Biosciences will present at the meeting demonstrate that AOC 1001 can effectively restore dystrophin expression in muscle cells and improve muscle function in mouse models of the disease. This is a significant step forward in the development of a potential treatment for Duchenne muscular dystrophy. The American Academy of Neurology Annual Meeting will be held virtually from April 17-22, 2023, and Avidity’s presentation will provide valuable insights into the potential of AOC 1001 to treat this debilitating disease.